How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma

When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in relapsed or refractory patients by comparing the res...

Descrición completa

Detalles Bibliográficos

Principais autores:	Treen Carson Michael Morris, Mary B. Drake, Paul J. Kettle, Tracey McGuigan, Maeve Leahy, Michael O’Dwyer, Helen Enright, Tanya O’Shea, Rakesh Popat, Heather E. Oakervee, Kwee Yong, Jamie D. Cavenagh, David A. Cairns, Alberto Alvarez-Iglesias, Gordon Cook
Formato:	Artigo
Idioma:	Inglês
Publicado:	SAABRON PRESS 2021-02-01
Series:	Clinical Hematology International
Assuntos:	Myeloma relapse bortezomib adriamycin dexamethasone response
Acceso en liña:	https://www.atlantis-press.com/article/125952406/view
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!